贝伐珠单抗联合化疗治疗晚期大肠癌的临床疗效  

Clinical effects of bevacizumab combined with chemotherapy for advanced colorectal cancer

作　　者：张洁[1] 班丽英[1] 

机构地区：[1]大连医科大学附属第一医院肿瘤科,辽宁省大连市116011

出　　处：《世界华人消化杂志》2015年第10期1674-1678,共5页World Chinese Journal of Digestology

摘　　要：目的:探讨对晚期大肠癌患者采用贝伐珠单抗联合化疗治疗的临床效果.方法:随机选取大连医科大学附属第一医院收治的178例晚期大肠癌患者,按照实际治疗方案分为观察组85例和对照组93例,观察组患者给予贝伐珠单抗联合化疗治疗,对照组患者给予XELOX方案治疗,比较两组患者的近期疗效、不良反应发生情况以及治疗后的生活质量.结果:观察组患者临床疗效显著优于对照组(67.06%vs 47.31%),差异具有统计学意义(P<0.05);两组患者骨髓抑制、神经毒性、肠胃道反应、肝肾毒性及免疫系统障碍发生率比较(25.88%vs 26.88%、17.65%vs 20.43%、20.00%vs 23.66%、15.29%vs 11.83%、11.76%vs 8.60%),差异无统计学意义(P>0.05);观察组患者化疗后各项生活质量评分无明显变化,与化疗前比较(65.62分±3.34分vs 67.83分±4.06分、67.67分±3.46分vs 69.26分±3.98分、66.15分±3.52分vs 68.11分±3.96分、66.58分±3.51分vs 68.02分±4.02分、66.83分±3.55分vs 68.39分±3.81分,差异无统计学意义(P>0.05);对照组患者化疗后各项生活质量评分均显著下降,与化疗前比较(51.57分±3.26分vs 67.89分±4.11分、54.62分±3.31分vs 69.30分±3.89分、53.24分±3.28分vs68.15分±3.92分、52.26分±3.22分vs 67.97分±4.11分、53.16分±3.28分vs 68.41分±3.80分),差异有统计学意义(P<0.05).结论:对晚期大肠癌患者采用贝伐珠单抗联合化疗治疗,能有提高患者的近期疗效,不增加化疗不良反应,对患者生活质量影响较小,值得推广.AIM：To evaluate the clinical effects of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer.METHODS：One hundred and seventy-eight patients with advanced colorectal cancer were divided into either an observation group（85 cases） or a control group（93 cases）.The observation group was treated by bevacizumab combined with chemotherapy,and the control group was treated by XELOX chemotherapy.The clinical effects,side effects,and quality of life were compared for the two groups.RESULTS：The response rate for the observation group was significantly better than that for the control group（67.06%vs 47.31%,P 〈0.05）.The rate of bone marrow suppression for the observation group was significantly lower than that for the control group（26.32%vs 50.54%,P 〈0.05）.There were no significant differences in the rates of bone marrow suppression,neurotoxicity,gastrointestinal reaction,liver and kidney toxicity,or immune system disorders（25.88%vs 26.88%,17.65%vs 20.43%,20.00%vs 23.66%,15.29%vs 11.83%,11.76%vs8.60%,P 〉0.05）.The scores of quality of life for the observation group posttreatment were similar to prior-treatment values（65.62 ± 3.34 vs 67.83 ± 4.06,67.67 ± 3.46 vs 69.26 ± 3.98,66.15± 3.52 vs 68.11 ± 3.96,66.58 ± 3.51 vs 68.02 ±4.02,66.83 ± 3.55 vs 68.39 ± 3.81,P 〉0.05）.The scores of quality of life for the control group were significantly lower after treatment than prior-treatment（51.57 ± 3.26 vs 67.89 ± 4.11,54.62 ± 3.31 vs 69.30 ± 3.89,53.24 ± 3.28 vs 68.15± 3.92,52.26 ± 3.22 vs 67.97 ± 4.11,53.16 ± 3.28 vs 68.41 ± 3.80,P 〈0.05）.CONCLUSION：Bevacizumab combined with chemotherapy has better clinical effects than chemotherapy alone in the treatment of advanced colorectal cancer,without significant impact on side effects and quality of life.

关 键 词：晚期大肠癌 贝伐珠单抗 化疗 

分 类 号：R735.34[医药卫生—肿瘤]